Clinical biomarkers and pathogenic‐related cytokines in rheumatoid arthritis
X Niu, G Chen - Journal of immunology research, 2014 - Wiley Online Library
Rheumatoid arthritis (RA) is a common autoimmune disease with unknown etiology and
pathogenesis. Although major therapeutic advances have been made in recent years, there …
pathogenesis. Although major therapeutic advances have been made in recent years, there …
Applications of protein microarrays in biomarker discovery for autoimmune diseases
S Li, G Song, Y Bai, N Song, J Zhao, J Liu… - Frontiers in …, 2021 - frontiersin.org
Dysregulated autoantibodies and cytokines were deemed to provide important cues for
potential illnesses, such as various carcinomas and autoimmune diseases. Increasing …
potential illnesses, such as various carcinomas and autoimmune diseases. Increasing …
A roadmap for investigating preclinical autoimmunity using patient-oriented and epidemiologic study designs: example of rheumatoid arthritis
Background & Aims Rheumatoid arthritis (RA) is a prototypic autoimmune disease causing
inflammatory polyarthritis that affects nearly 1% of the population. RA can lead to joint …
inflammatory polyarthritis that affects nearly 1% of the population. RA can lead to joint …
Preclinical disease and preventive strategies in IBD: perspectives, challenges and opportunities
IBDs, encompassing Crohn's disease (CD) and UC, are chronic, relapsing and remitting,
inflammatory diseases of the GI tract. IBD is emerging as a globally important disease with …
inflammatory diseases of the GI tract. IBD is emerging as a globally important disease with …
Autoimmunity to citrullinated proteins and the initiation of rheumatoid arthritis
VM Holers - Current opinion in immunology, 2013 - Elsevier
Highlights•RA exhibits a long preclinical period with autoantibodies and other
biomarkers.•Highly specific preclinical autoimmunity to citrullinated antigens develops …
biomarkers.•Highly specific preclinical autoimmunity to citrullinated antigens develops …
Serum inflammatory mediators as markers of human Lyme disease activity
Chemokines and cytokines are key signaling molecules that orchestrate the trafficking of
immune cells, direct them to sites of tissue injury and inflammation and modulate their states …
immune cells, direct them to sites of tissue injury and inflammation and modulate their states …
[HTML][HTML] A molecular signature of preclinical rheumatoid arthritis triggered by dysregulated PTPN22
HH Chang, GY Liu, N Dwivedi, B Sun, Y Okamoto… - JCI insight, 2016 - ncbi.nlm.nih.gov
A unique feature of rheumatoid arthritis (RA) is the presence of anti-citrullinated protein
antibodies (ACPA). Several risk factors for RA are known to increase the expression or …
antibodies (ACPA). Several risk factors for RA are known to increase the expression or …
Discerning risk of disease transition in relatives of systemic lupus erythematosus patients utilizing soluble mediators and clinical features
ME Munroe, KA Young, DL Kamen… - Arthritis & …, 2017 - Wiley Online Library
Objective Systemic lupus erythematosus (SLE) and other autoimmune diseases cause
significant morbidity. Identifying populations at risk of developing SLE is essential for …
significant morbidity. Identifying populations at risk of developing SLE is essential for …
Interleukin-9 and T helper type 9 cells in rheumatic diseases
F Ciccia, G Guggino, A Ferrante… - Clinical & …, 2016 - academic.oup.com
Summary Interleukin (IL)-9 is a 28-30 kDa monomeric glycosylated polypeptide belonging to
the IL-7/IL-9 family of proteins that bind to a composite receptor consisting of the private …
the IL-7/IL-9 family of proteins that bind to a composite receptor consisting of the private …
Strategies to predict rheumatoid arthritis development in at-risk populations
EW Karlson, D Van Schaardenburg… - …, 2016 - academic.oup.com
The development of RA is conceived as a multiple hit process and the more hits that are
acquired, the greater the risk of developing clinically apparent RA. Several at-risk phases …
acquired, the greater the risk of developing clinically apparent RA. Several at-risk phases …